Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18:

Osteosarcoma Clinical Trial

Official title:

Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18: Examination of Osteosarcoma Tissue Samples From Two Family Members for Loss of Heterozygosity in the Chromosome 18 Region, Genetically Linked With Paget's Disease of Bone

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00615628
• Other study ID #: Osteosarcoma & Paget's Disease
• Secondary ID: IRB #4168
• Status: Terminated
• Phase: N/A
• First received: February 1, 2008
• Last updated: May 29, 2013
• Start date: April 2002
• Est. completion date: December 2009

Study information

• Verified date: May 2013
• Source: State University of New York - Upstate Medical University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Researchers have previously demonstrated loss of heterozygosity in a region on chromosome 18q, associated with osteogenic sarcomas in bone affected by Paget's disease. The loci used in this study are specifically described by those authors as showing loss of heterozygosity in 6 of 7 affected families.

Description:

As above, no additional information

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• This is a familial study therefore the only inclusion/exclusion criteria would be that subjects must be a blood relative and over the age of 18.

• The subjects are proband and father along with unaffected blood relatives. Their peripheral blood will act as a control and provide information to delineate the inheritance from the father, as seen in the son.

Exclusion Criteria:

• Not part of the family

Study Design

Observational Model: Family-Based, Time Perspective: Prospective

Related Conditions & MeSH terms

• Osteosarcoma
• Paget's Disease

Locations

Country	Name	City	State
United States	SUNY Upstate Medical University	Syracuse	New York

Sponsors (1)

Lead Sponsor	Collaborator
State University of New York - Upstate Medical University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Loss of heterozygosity	A loss of heterozygosity of a proposed tumor suppressor gene on chromosome 18	January, 2000 through February 2009	No